Wojtukiewicz M Z, Tang D G, Ciarelli J J, Nelson K K, Walz D A, Diglio C A, Mammen E F, Honn K V
Department of Radiation Oncology, Wayne State University, Detroit, MI.
Int J Cancer. 1993 Jul 9;54(5):793-806. doi: 10.1002/ijc.2910540514.
Initial arrest of tumor cells in the microvasculature and their attachment to the endothelium and subendothelial matrix (SEM) are essential prerequisites for metastasis to occur. Factors mediating these interactions are viewed as important determinants of the tumor-cell metastatic phenotype. In this work we have studied the effects of thrombin, its analogs and its precursors on the adhesive properties and metastatic potential of tumor cells. We show that alpha-thrombin, the native form of the key coagulation enzyme, is capable of enhancing tumor-cell adhesion to both the endothelium and SEM components represented by fibronectin. Subclotting, physiological concentrations of alpha-thrombin produced a 2- to 5-fold increase in tumor-cell adhesion. A bell-shaped dose-response curve was observed, with maximal effect at 0.1 U/ml. Maximum effect occurred when cells were exposed to the agonist for 15 min and exposure for up to 4 hr resulted in enhanced tumor-cell adhesion. Prolonged incubation with thrombin resulted in a decline in the thrombin-enhanced adhesion which reached unstimulated control levels by 24 hr. Thrombin precursors and active-site-inhibited thrombin analogs only had minimal adhesion-enhancing activity; nitro- and exosite-alpha-thrombin, which retain a functional active site, mimicked, although to a lesser degree, the action of alpha-thrombin. Tumor-cell incubation with thrombin resulted in an upregulated cell-surface expression of the alpha11b beta 3 integrin, a receptor mediating interactions between tumor cells and endothelial cells, and between tumor cells and SEM. Antibodies against alpha 11b beta 3 integrin effectively inhibited thrombin-enhanced tumor-cell adhesion. Thrombin effects on tumor cells involved the PKC signal transduction pathway as thrombin-enhanced adhesion was inhibited by pre-incubation with PKC inhibitors and a transient PKC translocation from cytosol to membrane was observed following thrombin challenge. In vivo, thrombin-treated tumor cells demonstrated a 2-fold increase in their lung-colonizing ability. In contrast to the adhesion results, the metastasis-enhancing effects of alpha-thrombin were mimicked by a thrombin precursor (prothrombin) and thrombin analogs.
肿瘤细胞在微血管中的初始滞留及其与内皮细胞和内皮下基质(SEM)的附着是发生转移的重要前提条件。介导这些相互作用的因素被视为肿瘤细胞转移表型的重要决定因素。在这项研究中,我们研究了凝血酶、其类似物及其前体对肿瘤细胞黏附特性和转移潜能的影响。我们发现,关键凝血酶的天然形式α-凝血酶能够增强肿瘤细胞与内皮细胞以及由纤连蛋白代表的SEM成分的黏附。亚凝血浓度的生理性α-凝血酶可使肿瘤细胞黏附增加2至5倍。观察到呈钟形的剂量反应曲线,在0.1 U/ml时效果最佳。当细胞暴露于激动剂15分钟时出现最大效应,暴露长达4小时会导致肿瘤细胞黏附增强。与凝血酶长时间孵育会导致凝血酶增强的黏附下降,到24小时时降至未刺激的对照水平。凝血酶前体和活性位点被抑制的凝血酶类似物仅具有最小的黏附增强活性;保留功能性活性位点的硝基-α-凝血酶和外位点-α-凝血酶虽然程度较小,但模拟了α-凝血酶的作用。用凝血酶孵育肿瘤细胞会导致α11bβ3整合素的细胞表面表达上调,α11bβ3整合素是一种介导肿瘤细胞与内皮细胞以及肿瘤细胞与SEM之间相互作用的受体。针对α11bβ3整合素的抗体可有效抑制凝血酶增强的肿瘤细胞黏附。凝血酶对肿瘤细胞的作用涉及PKC信号转导途径,因为凝血酶增强的黏附会被用PKC抑制剂预孵育所抑制,并且在凝血酶刺激后观察到PKC从胞质溶胶到细胞膜的短暂转位。在体内,经凝血酶处理的肿瘤细胞在肺定植能力上增加了2倍。与黏附结果相反,α-凝血酶的转移增强作用被凝血酶前体(凝血酶原)和凝血酶类似物所模拟。